The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)

CA262105

48535 (ClinVar)

Gene: USH2A
Condition: Usher syndrome
Inheritance Mode: Autosomal recessive inheritance
UUID: 16f373e0-f3cf-4ebe-91ea-6d1a22e44f9c

HGVS expressions

NM_206933.2:c.5581G>A
NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)
NC_000001.11:g.216073292C>T
CM000663.2:g.216073292C>T
NC_000001.10:g.216246634C>T
CM000663.1:g.216246634C>T
NC_000001.9:g.214313257C>T
NG_009497.1:g.355105G>A
NR_125992.1:n.136+692C>T
NR_125993.1:n.136+692C>T
NM_206933.3:c.5581G>A
ENST00000307340.7:c.5581G>A

Pathogenic

Met criteria codes 6
PM3_Strong PS4 PM2_Supporting PP3 PP1 PP4
Not Met criteria codes 17
BA1 BS1 BS4 BS2 BP7 BP5 PVS1 BP4 BP2 BP3 PS1 PS3 PS2 PM6 PM5 PM4 PM1

Evidence Links 4

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hearing Loss VCEP
The allele frequency of the p.Gly1861Ser variant in USH2A is 0.017% (3/17184) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). This variant has been detected in 4 patients with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3_S; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). The variant has been reported to segregate with hearing loss in one affected family member (PP1, PMID: 26310143). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). Computational prediction tools and conservation analysis suggest that the p.Gly1861Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PM2_P, PP3, PM3_S, PP1, PP4.
Met criteria codes
PM3_Strong
I gave 1 point for the splicing variant in trans, 1 point for the nonsense variant, and 0.5 for two of the missense variants= 2.5 pts There is also an LMM case that has the same -2 splice variant as Jiang et al, but this would still not bump up to VS.

PS4
Cases: 5/504 Asian alleles gnomAD: 3/17184 Asian alleles Chi-square with Yates correction: Chi squared equals 82.448 with 1 degrees of freedom. The two-tailed P value is less than 0.0001.The association between rows (groups) and columns (outcomes) is considered to be extremely statistically significant.
PM2_Supporting
Variant is too frequent to meet PM2_supporting. -ANDREA: disagree; meets PM2 supporting, since it is at 0.017% of East Asian chroms and cutoff is 0.07%.
PP3
Our cutoff is >0.7 and the variant is 0.786, so PP3 is met. No splicing impact is predicted.
PP1
The proband and 1 affected sib carry this variant.

PP4
Many of the reported patients had Usher syndrome and were negative for variants in other Usher syndrome genes.
Not Met criteria codes
BA1
Variant is too frequent to meet PM2_supporting. -ANDREA: disagree; meets PM2 supporting, since it is at 0.017% of East Asian chroms and cutoff is 0.07%.
BS1
Variant is too frequent to meet PM2_supporting. -ANDREA: disagree; meets PM2 supporting, since it is at 0.017% of East Asian chroms and cutoff is 0.07%.
BS4
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
Our cutoff is >0.7 and the variant is 0.786, so PP3 is met. No splicing impact is predicted.
BP2
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Approved on: 2018-09-14
Published on: 2019-07-17
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.